'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

Source: 
Endpoints
snippet: 

Catalent is staying on the growth track.

Just two months after committing $1.2 billion to pick up Paragon and take a deep dive into the sizzling hot gene therapy manufacturing sector, the CDMO is bouncing right back with a deal to buy out Bristol-Myers’ central launchpad for new therapies in Europe, acquiring a complex in Anagni, Italy, southwest of Rome, that will significantly expand its capacity on the continent.